n/a
Mollica V., Rizzo A., Massari F. (2021). Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?. EUROPEAN UROLOGY ONCOLOGY, 4(5), 854-854 [10.1016/j.euo.2021.06.008].
Re: Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, et al. Pembrolizumab Alone or Combined with Chemotherapy Versus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-label, Phase 3 Trial. Lancet Oncol. In press. https://doi.org/10.1016/S1470-2045(21)00152-2: The Conflict of Adding Immunotherapy to Chemotherapy in Metastatic Urothelial Carcinoma: A Matter of the Right Timing?
Mollica V.;Rizzo A.;Massari F.
2021
Abstract
n/aFile in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
